[1] Washkowitz AJ, Gavrilov S, Begum S, et al. Diverse functional networks of Tbx3 in development and disease[J]. Wiley Interdiscip Rev Syst Biol Med, 2012, 4(3): 273-283.
[2] Gavrilov S, Harvey RP, Papaioannou VE. Lack of genetic interaction between Tbx20 and Tbx3 in early mouse heart development[J]. PLoS One, 2013, 8(7): e70149.
[3] Douglas NC, Papaioannou VE. The Tbox transcription factors TBX2 and TBX3 in mammary gland development and breast cancer[J]. J Mammary Gland Biol Neoplasia, 2013, 18(2): 143-147.
[4] Ballim RD, Mendelsohn C, Papaioannou VE, et al. The ulnarmammary syndrome gene, Tbx3, is a direct target of the retinoic acid signaling pathway, which regulates its expression during mouse limb development[J]. Mol Biol Cell, 2012, 23(12): 2362-2372.
[5] Hoogaars WM, Engel A, Brons JF, et al. Tbx3 controls the sinoatrial node gene program and imposes pacemaker function on the atria[J]. Genes Dev, 2007, 21(9): 1098-1112.
[6] Lu R, Yang A, Jin Y. Dual functions of Tbox 3 (Tbx3) in the control of selfrenewal and extraembryonic endoderm differentiation in mouse embryonic stem cells[J]. J Biol Chem, 2011, 286(10): 8425-8436.
[7] Weidgang CE, Russell R, Tata PR, et al. TBX3 directs cellfate decision toward mesendoderm[J]. Stem Cell Reports, 2013, 1(3): 248265.
[8] Guo F, Parker Kerrigan BC, Yang D, et al. Posttranscriptional regulatory network of epithelialtomesenchymal and mesenchymaltoepithelial transitions[J]. J Hematol Oncol, 2014, 7: 19.
[9] Rodriguez M, Aladowicz E, Lanfrancone L, et al. Tbx3 represses Ecadherin expression and enhances melanoma invasiveness[J]. Cancer Res, 2008, 68(19): 7872-7881.
[10] Boyd SC, Mijatov B, Pupo GM, et al. Oncogenic BRAF(V600E) signaling induces the TBox3 transcriptional repressor to repress Ecadherin and enhance melanoma cell invasion[J]. J Invest Dermatol, 2013, 133(5): 12691277.
[11] Du HF, Ou LP, Yang X, et al. A new PKCα/β/TBX3/Ecadherin pathway is involved in PLCεregulated invasion and migration in human bladder cancer cells[J]. Cell Signal, 2014, 26(3): 580-593.
[12] Yu Z, Pestell TG, Lisanti MP, et al. Cancer stem cells[J]. Int J Biochem Cell Biol, 2012, 44(12): 2144-2151.
[13] Amini S, Fathi F, Mobalegi J, et al. The expressions of stem cell markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in bladder, colon, and prostate cancer, and certain cancer cell lines[J]. Anat Cell Biol, 2014, 47(1): 1-11.
[14] Fillmore CM, Gupta PB, Rudnick JA, et al. Estrogen expands breast cancer stemlike cells through paracrine FGF/Tbx3 signaling[J]. Proc Natl Acad Sci USA, 2010, 107(50): 21737-21742.
[15] Liu J, Esmailpour T, Shang X, et al. TBX3 overexpression causes mammary gland hyperplasia and increases mammary stemlike cells in an inducible transgenic mouse model[J]. BMC Dev Biol, 2011, 11: 65.
[16] Renard CA, Labalette C, Armengol C, et al. Tbx3 is a downstream target of the Wnt/betacatenin pathway and a critical mediator of betacatenin survival functions in liver cancer[J]. Cancer Res, 2007, 67(3): 901-910.
[17] Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer[J]. Oncogene, 2010, 29(34): 4741-4751.
[18] Chiou SH, Wang ML, Chou YT, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem celllike properties and epithelialmesenchymal transdifferentiation[J]. Cancer Res, 2010, 70(24): 10433-10444.
[19] Asiedu MK, BeauchampPerez FD, Ingle JN, et al. AXL induces epithelialtomesenchymal transition and regulates the function of breast cancer stem cells[J]. Oncogene, 2014, 33(10): 13161324.
[20] Mani SA, Guo W, Liao MJ, et al. The epithelialmesenchymal transition generates cells with properties of stem cells[J]. Cell, 2008, 133(4): 704-715.
[21] Lan L, Luo Y, Cui D, et al. Epithelialmesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells[J]. Int J Oncol, 2013, 43(1): 113-120.
[22] Masui T, Ota I, Yook JI, et al. Snailinduced epithelialmesenchymal transition promotes cancer stem celllike phenotype in head and neck cancer cells[J]. Int J Oncol, 2014, 44(3): 693-699.
[23] Patai AV, Molnár B, Kalmár A, et al. Role of DNA methylation in colorectal carcinogenesis[J]. Dig Dis, 2012, 30(3): 310-315.
[24] Kang C, Song JJ, Lee J, et al. Epigenetics: an emerging player in gastric cancer[J]. World J Gastroenterol, 2014, 20(21): 6433-6447.
[25] Kandimalla R, van Tilborg AA, Kompier LC, et al. Genomewide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTaspecific prognostic markers[J]. Eur Urol, 2012, 61(6): 1245-1256.
[26] Li J, Weinberg MS, Zerbini L, et al. The oncogenic TBX3 is a downstream target and mediator of the TGFβ1 signaling pathway[J]. Mol Biol Cell, 2013, 24(22): 3569-3576.
[27] Burgucu D, Guney K, Sahinturk D, et al. Tbx3 represses PTEN and is overexpressed in head and neck squamous cell carcinoma[J]. BMC cancer, 2012, 12: 481.
[28] Renard CA, Labalette C, Armengol C, et al. Tbx3 is a downstream target of the Wnt/betacatenin pathway and a critical mediator of betacatenin survival functions in liver cancer[J]. Cancer Res, 2007, 67(3): 901-910. |